

Marina Berenguer

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2034239/marina-berenguer-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

184
papers

10,305
citations

49
h-index

99
g-index

253
ext. papers

12,059
ext. citations

4.3
avg, IF

6.38
L-index

#	Paper	IF	Citations
184	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018 , 69, 461-511	13.4	1079
183	HCV-related fibrosis progression following liver transplantation: increase in recent years. <i>Journal of Hepatology</i> , 2000 , 32, 673-84	13.4	642
182	Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. <i>Hepatology</i> , 2002 , 36, 202-10	11.2	500
181	High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. <i>Hepatology</i> , 1999 , 29, 250-6	11.2	442
180	Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. <i>Hepatology</i> , 2000 , 32, 852-8	11.2	432
179	Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 5692-7	11.5	365
178	Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. <i>Journal of Hepatology</i> , 2008 , 49, 274-87	13.4	286
177	Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. <i>American Journal of Transplantation</i> , 2008 , 8, 679-87	8.7	243
176	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , 2020 , 73, 1170-1218	13.4	237
175	Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. <i>Journal of Hepatology</i> , 2016 , 65, 524-31	13.4	235
174	Hepatitis C and liver transplantation. <i>Journal of Hepatology</i> , 2001 , 35, 666-78	13.4	231
173	Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. <i>Lancet, The</i> , 2015 , 385, 2502-9	4.0	220
172	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. <i>Liver Transplantation</i> , 2007 , 13, 349-60	4.5	204
171	Natural history of recurrent hepatitis C. <i>Liver Transplantation</i> , 2002 , 8, S14-8	4.5	202
170	Contribution of obesity to hepatitis C-related fibrosis progression. <i>American Journal of Gastroenterology</i> , 2002 , 97, 2408-14	0.7	172
169	A model to predict severe HCV-related disease following liver transplantation. <i>Hepatology</i> , 2003 , 38, 34-41	11.2	171
168	De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. <i>Liver Transplantation</i> , 2001 , 7, 51-8	4.5	151

167	Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. <i>Journal of Hepatology</i> , 2006 , 44, 717-22	13.4	149
166	Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. <i>Journal of Hepatology</i> , 1998 , 28, 756-63	13.4	144
165	Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. <i>Liver Transplantation</i> , 2007 , 13, 21-9	4.5	134
164	Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , 2006 , 12, 1067-76	4.5	131
163	What determines the natural history of recurrent hepatitis C after liver transplantation?. <i>Journal of Hepatology</i> , 2005 , 42, 448-56	13.4	118
162	De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years?. <i>American Journal of Transplantation</i> , 2004 , 4, 596-604	8.7	113
161	Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. <i>Journal of Hepatology</i> , 2013 , 58, 1028-41	13.4	111
160	Reversion of disease manifestations after HCV eradication. <i>Journal of Hepatology</i> , 2016 , 65, S95-S108	13.4	108
159	Treating hepatitis C infection in liver transplant recipients. <i>Liver Transplantation</i> , 2006 , 12, 1192-204	4.5	108
158	Are posttransplantation protocol liver biopsies useful in the long term?. <i>Liver Transplantation</i> , 2001 , 7, 790-6	4.5	104
157	Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. <i>Journal of Hepatology</i> , 2011 , 55, 207-17	13.4	92
156	Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. <i>Liver Transplantation</i> , 2003 , 9, 228-35	4.5	89
155	International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. <i>Transplantation</i> , 2018 , 102, 727-743	1.8	84
154	Lessons learned from anatomic variants of the hepatic artery in 1,081 transplanted livers. <i>Liver Transplantation</i> , 2007 , 13, 1401-4	4.5	82
153	Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. <i>Liver Transplantation</i> , 2008 , 14, 1449-60	4.5	79
152	Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. <i>Hepatology</i> , 2015 , 62, 575-83	11.2	78
151	Host and donor risk factors before and after liver transplantation that impact HCV recurrence. <i>Liver Transplantation</i> , 2003 , 9, S44-7	4.5	77
150	Post-liver transplantation medical complications. <i>Annals of Hepatology</i> , 2006 , 5, 77-85	3.1	76

149	Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. <i>Hepatology</i> , 1999 , 30, 1513-20	11.2	75
148	Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. <i>Journal of Hepatology</i> , 2011 , 55, 820-7	13.4	68
147	Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. <i>Liver Transplantation</i> , 2006 , 12, 762-7	4.5	66
146	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , 2017 , 101, 945-955	1.8	63
145	HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans. <i>Science Translational Medicine</i> , 2014 , 6, 242ra81	17.5	60
144	ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. <i>Journal of Hepatology</i> , 2017 , 67, 585-602	13.4	57
143	Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. <i>Liver Transplantation</i> , 2009 , 15, 738-46	4.5	57
142	Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. <i>Transplantation</i> , 2010 , 90, 1204-9	1.8	54
141	Treatment of chronic hepatitis C in hemodialysis patients. <i>Hepatology</i> , 2008 , 48, 1690-9	11.2	54
140	Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. <i>Kidney International</i> , 2018 , 94, 663-673	9.9	54
139	Outcomes in liver transplantation: does sex matter?. <i>Journal of Hepatology</i> , 2015 , 62, 946-55	13.4	51
138	Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. <i>Liver Transplantation</i> , 2005 , 11, 456-62	4.5	50
137	Liver transplantation and hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011 , 35, 805-12	2.4	49
136	Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. <i>Liver Transplantation</i> , 2009 , 15, 79-87	4.5	47
135	Liver Transplantation for Alcoholic Liver Disease. <i>Transplantation</i> , 2016 , 100, 981-7	1.8	44
134	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. <i>Journal of Hepatology</i> , 2012 , 57, 297-305	13.4	42
133	Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?. <i>Liver Transplantation</i> , 2002 , 8, 1020-7	4.5	42
132	International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. <i>Transplantation</i> , 2019 , 103, 45-56	1.8	42

131	Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?. <i>Liver Transplantation</i> , 2003 , 9, 1152-8	4.5	41
130	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , 2017 , 101, 956-967	1.8	40
129	Risk of extended criteria donors in hepatitis C virus-positive recipients. <i>Liver Transplantation</i> , 2008 , 14 Suppl 2, S45-50	4.5	40
128	Long-term outcome of long-term liver transplant survivors. <i>Transplant International</i> , 2013 , 26, 740-50	3	37
127	Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. <i>Liver International</i> , 2018 , 38, 2170-2177	7.9	36
126	Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. <i>Journal of Hepatology</i> , 2012 , 56, 1310-6	13.4	36
125	Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors. <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 1255-61	2.2	35
124	Equally Interchangeable? How Sex and Gender Affect Transplantation. <i>Transplantation</i> , 2019 , 103, 1094-1101	1.8	35
123	Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 1207-12	2.2	32
122	Recurrence of hepatitis C after liver transplantation. <i>Annals of Gastroenterology</i> , 2013 , 26, 304-313	2.2	32
121	Treatment of hepatitis C after liver transplantation. <i>Clinics in Liver Disease</i> , 2005 , 9, 579-600, vi	4.6	31
120	Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. <i>Transplantation</i> , 2011 , 92, 334-40	1.8	31
119	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 328-349	0.9	30
118	227 LONG-TERM RESULTS WITH THE USE OF GRAFTS FROM HBSAG NEGATIVE HBCAB POSITIVE DONORS IN LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2008 , 48, S93	13.4	30
117	COVID-19 and liver transplantation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 526-528	24.2	30
116	Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , 2013 , 59, 1323-30	13.4	29
115	Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. <i>Liver Transplantation</i> , 2014 , 20, 25-34	4.5	28
114	Performance of the OraQuick Hepatitis C virus antibody test in oral fluid and fingerstick blood before and after treatment-induced viral clearance. <i>Journal of Clinical Virology</i> , 2018 , 102, 77-83	14.5	27

113	Combined resistance and endurance training at a moderate-to-high intensity improves physical condition and quality of life in liver transplant patients. <i>Liver Transplantation</i> , 2017 , 23, 1273-1281	4.5	26
112	Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. <i>Liver Transplantation</i> , 2015 , 21, 812-22	4.5	26
111	Should organs from hepatitis C-positive donors be used in hepatitis C-negative recipients for liver transplantation?. <i>Liver Transplantation</i> , 2018 , 24, 831-840	4.5	25
110	Chronic kidney disease after liver transplantation: pretransplantation risk factors and predictors during follow-up. <i>Transplantation</i> , 2013 , 95, 1148-53	1.8	24
109	Comparative prospective study of two liver graft preservation solutions: University of Wisconsin and Celsior. <i>Liver Transplantation</i> , 2009 , 15, 1709-17	4.5	24
108	Hepatitis C after liver transplantation: risk factors, outcomes, and treatment. <i>Current Opinion in Organ Transplantation</i> , 2005 , 10, 81-89	2.5	20
107	Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies. <i>Hemodialysis International</i> , 2018 , 22 Suppl 1, S8-S21	1.7	19
106	Hot topic in hepatitis C virus research: the type of immunosuppression does not matter. <i>Liver Transplantation</i> , 2011 , 17 Suppl 3, S24-8	4.5	18
105	Control of blood pressure in liver transplant recipients. <i>Transplantation</i> , 2012 , 93, 1031-7	1.8	18
104	Management of hepatitis C virus in the transplant patient. <i>Clinics in Liver Disease</i> , 2007 , 11, 355-76	4.6	18
103	Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: role of an aggressive approach. <i>Liver Transplantation</i> , 2013 , 19, 69-77	4.5	17
102	Computational models of liver fibrosis progression for hepatitis C virus chronic infection. <i>BMC Bioinformatics</i> , 2014 , 15 Suppl 8, S5	3.6	16
101	Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant. <i>International Journal of Biostatistics</i> , 2010 , 6, Article 7	1.3	16
100	Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. <i>Liver Transplantation</i> , 2009 , 15, 1798-807	4.5	16
99	Iberogast-Induced Severe Hepatotoxicity Leading to Liver Transplantation. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1364-5	0.7	15
98	Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. <i>Liver International</i> , 2012 , 32, 712-31	7.9	15
97	Stretching the boundaries for liver transplant in the 21st century. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 803-811	18.8	15
96	Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis: Is the Point of No Return the Same Before and After Liver Transplantation? A Review. <i>Transplantation</i> , 2017 , 101, 916-923	1.8	14

95	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopenia and hypoalbuminaemia. <i>Liver International</i> , 2015 , 35, 2358-62	7.9	14
94	Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , 2004 , 10, 217-27	4.5	14
93	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 579-592	0.9	13
92	Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States. <i>Transplantation</i> , 2020 , 104, 2078-2086	1.8	13
91	Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). <i>Liver International</i> , 2018 , 38, 1022-1027	7.9	13
90	O004 : On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis c virus genotype 1b infection after orthotopic liver transplantation (OLT): Interim data from the phase II saturn study. <i>Journal of Hepatology</i> , 2015 , 62, S191-S192	13.4	12
89	Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain. <i>Journal of Hepatology</i> , 2018 , 69, 966-968	13.4	12
88	Response to different therapeutic approaches in Wilson disease. A long-term follow up study. <i>Annals of Hepatology</i> , 2012 , 11, 907-914	3.1	12
87	Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. <i>Liver Transplantation</i> , 2011 , 17, 1318-27	4.5	12
86	Immunosuppression in liver transplant. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2020 , 46-47, 101681	2.5	12
85	Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2819-2821	6.9	11
84	Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. <i>Liver Transplantation</i> , 2020 , 26, 866-877	4.5	11
83	Are HCV-infected individuals candidates for hepatitis A vaccine?. <i>Lancet, The</i> , 1998 , 351, 924-5	4.0	11
82	Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. <i>Annals of Surgery</i> , 2021 , 273, 483-493	7.8	11
81	Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. <i>World Journal of Gastroenterology</i> , 2016 , 22, 4547-58	5.6	11
80	Controlling Diabetes After Liver Transplantation: Room for Improvement. <i>Transplantation</i> , 2016 , 100, e66-e73	1.8	11
79	Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2019 , 171, 496-504	8	11
78	Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. <i>Transplant Infectious Disease</i> , 2017 , 19, e12696	2.7	10

77	Fat and liver transplantation: clinical implications. <i>Transplant International</i> , 2018 , 31, 828-837	3	10
76	Comparison of results of combined liver-kidney transplantation vs. isolated liver transplantation. <i>Annals of Hepatology</i> , 2013 , 12, 274-281	3.1	10
75	Antiviral therapy in patients with HCV-cirrhosis. <i>Annals of Hepatology</i> , 2009 , 8, 292-297	3.1	10
74	Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020 , 104, 1143-1149	1.8	10
73	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 597-608	0.9	10
72	Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis. <i>Annals of Hepatology</i> , 2019 , 18, 855-861	3.1	9
71	Genetics of Wilson disease and Wilson-like phenotype in a clinical series from eastern Spain. <i>Clinical Genetics</i> , 2020 , 97, 758-763	4	9
70	Pushing the donor limits: Deceased donor liver transplantation using organs from octogenarian donors. <i>Liver Transplantation</i> , 2017 , 23, S22-S26	4.5	9
69	Indications for and results of liver retransplantation. <i>Transplantation Proceedings</i> , 2009 , 41, 1016-7	1.1	9
68	Non-invasive biomarkers of liver fibrosis in liver transplant patients with hepatitis C: can we avoid liver biopsies?. <i>Digestive and Liver Disease</i> , 2009 , 41, 226-8	3.3	9
67	Live donor liver transplantation for hepatitis C: new data, old story. <i>Liver Transplantation</i> , 2006 , 12, 516-9.5	4.5	9
66	Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease. <i>Clinics in Liver Disease</i> , 2003 , 7, 631-50, vii	4.6	9
65	Treatment of recurrence of hepatitis B in transplant patients. <i>Journal of Hepatology</i> , 2003 , 39 Suppl 1, S190-3	13.4	8
64	An objective definition for clinical suspicion of T-cell-mediated rejection after liver transplantation. <i>Clinical Transplantation</i> , 2017 , 31, e13005	3.8	7
63	Liver Volume as a Predictor of Functional Improvement Post-DAA Treatment. <i>Transplantation</i> , 2018 , 102, e74-e81	1.8	7
62	Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir. <i>Annals of Hepatology</i> , 2013 , 12, 974-978	3.1	7
61	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. <i>Transplantation</i> , 2020 , 104, 2087-2096	1.8	7
60	Wilson's Disease: Facing the Challenge of Diagnosing a Rare Disease. <i>Biomedicines</i> , 2021 , 9,	4.8	7

59	Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observational, retrospective study. <i>Transplant International</i> , 2018 , 31, 649-657	3	6
58	Hepatitis C virus viral kinetics during E2a or E2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes. <i>Journal of Clinical Virology</i> , 2012 , 53, 231-8	14.5	6
57	The ILTS Consensus Conference on NAFLD/NASH and Liver Transplantation: Setting the Stage. <i>Transplantation</i> , 2019 , 103, 19-21	1.8	6
56	Hepatitis C-related cirrhosis. Current status. <i>Medicina Clínica</i> , 2017 , 148, 78-85	1	5
55	The New Era of Hepatitis C: Therapy in Liver Transplant Recipients. <i>Clinics in Liver Disease</i> , 2017 , 21, 421-434	4.34	5
54	Management of HCV in the liver transplant setting. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39 Suppl 1, S115-9	2.4	5
53	A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area. <i>PLoS ONE</i> , 2020 , 15, e0228351	3.7	5
52	Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS). <i>Journal of Hepatology</i> , 2021 ,	13.4	5
51	Overcoming drug resistance in HSV, CMV, HBV and HCV infection. <i>Future Microbiology</i> , 2015 , 10, 1759-66.9	6.9	4
50	Alterations in carbohydrate metabolism in cirrhotic patients before and after liver transplant. <i>Diabetes Research and Clinical Practice</i> , 2015 , 110, 123-8	7.4	4
49	Acute cellular rejection versus recurrent hepatitis C after liver transplantation: Clinical and pathological features driving a rational diagnostic approach. <i>Hepatology Research</i> , 2015 , 45, 423-31	5.1	4
48	Liver. <i>American Journal of Gastroenterology</i> , 2014 , 109 Suppl 2, S123-87	0.7	4
47	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 862-873	0.9	4
46	Characteristics, Trends, and Outcomes of Liver Transplantation for Primary Sclerosing Cholangitis in Female Versus Male Patients: An Analysis From the European Liver Transplant Registry. <i>Transplantation</i> , 2021 , 105, 2255-2262	1.8	4
45	Long-term outcomes of the octogenarian donor liver recipient: The era of the new centurion. <i>Clinical Transplantation</i> , 2019 , 33, e13629	3.8	2
44	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 579-592	0.1	2
43	Delisting of liver transplant candidates with chronic hepatitis C virus infection after viral eradication: outcome after delisting: a European study. <i>Journal of Hepatology</i> , 2017 , 66, S39-S40	13.4	2
42	Pilot validation study of a rapid test in oral fluid for population screening of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017 , 66, S403-S404	13.4	2

41	94 CALCINEURIN INHIBITORS AND OUTCOME OF LIVER TRANSPLANTATION IN HCV-POSITIVE RECIPIENTS: FINAL RESULTS OF A PROSPECTIVE RANDOMIZED STUDY. <i>Journal of Hepatology</i> , 2010 , 52, S43	13.4	2
40	Viral hepatitis after liver transplantation. <i>Hepatology Research</i> , 2007 , 37 Suppl 2, S279-86	5.1	2
39	Changing delta hepatitis patient profile: A single center experience in Valencia region, Spain. <i>World Journal of Hepatology</i> , 2020 , 12, 277-287	3.4	2
38	Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registry. <i>American Journal of Transplantation</i> , 2021 ,	8.7	2
37	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018 , 110, 641-649	0.9	2
36	The road map toward an hepatitis C virus-free transplant population. <i>American Journal of Transplantation</i> , 2018 , 18, 2409-2416	8.7	2
35	Remnant vital tissue following locoregional therapy for hepatocellular carcinoma: another player in the game. <i>Transplant International</i> , 2018 , 31, 972	3	1
34	Reply to: "Renal impairment and anemia during triple therapy". <i>Journal of Hepatology</i> , 2014 , 60, 1100-1	13.4	1
33	Beyond cure: preventing and managing the complications of end-stage liver disease. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 355-60	4.2	1
32	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015 , 14, 477-486	3.1	1
31	Optimum minimization strategies in hepatitis C virus infected liver transplant. <i>Current Opinion in Organ Transplantation</i> , 2007 , 12, 641-646	2.5	1
30	Hepatitis C virus in liver transplantation: impact and treatment of hepatitis C virus recurrence. <i>Current Opinion in Organ Transplantation</i> , 2006 , 11, 599-607	2.5	1
29	Characteristics and impact of sex in a cohort of patients with primary sclerosing cholangitis: Experience of a transplant center in the Mediterranean basin. <i>Gastroenterología Y Hepatología</i> , 2021 ,	0.9	1
28	Frailty and Sarcopenia in Acute-on-Chronic Liver Failure. <i>Hepatology Communications</i> , 2021 , 5, 1333-1347		1
27	Last gasps of the hepatitis C virus dragon: Direct acting antiviral failures and hepatitis C virus-positive donors. <i>Liver Transplantation</i> , 2016 , 22, 47-51	4.5	1
26	Peritransplant Antiviral Treatment of Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. <i>Liver Transplantation</i> , 2018 , 24, 1476-1480	4.5	1
25	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 328-349	0.1	1
24	Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. <i>Annals of Hepatology</i> , 2016 , 15, 512-23	3.1	1

23	The ILTS-SETH Consensus Conference on Extrahepatic Cancer and Liver Transplantation: Paving the Way.. <i>Transplantation</i> , 2022 , 106, e1-e2	1.8	1
22	Hepatitis C-related cirrhosis. Current status. <i>Medicina Clínica (English Edition)</i> , 2017 , 148, 78-85	0.3	0
21	Cytomegalovirus specific polyfunctional T-cell responses expressing CD107a predict control of CMV infection after liver transplantation. <i>Cellular Immunology</i> , 2021 , 371, 104455	4.4	0
20	Gender Disparities in Liver Transplantation 2020 , 329-339		0
19	Posttransplant Calcineurin Inhibitors Levels and Inpatient Variability Are Not Associated With Long-term Outcomes Following Liver Transplantation. <i>Transplantation</i> , 2020 , 104, 1201-1209	1.8	0
18	Milan-out Criteria and Worse Intention-to-Treat Outcome Postliver Transplantation. <i>Transplantation Direct</i> , 2019 , 5, e487	2.3	0
17	Hepatic steatosis and steatohepatitis: a functional meta-analysis of sex-based differences in transcriptomic studies. <i>Biology of Sex Differences</i> , 2021 , 12, 29	9.3	0
16	Transplantation for Hepatitis C 2015 , 131-152		
15	Liver Websites. <i>Transplantation</i> , 2016 , 100, 1594	1.8	
14	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir/Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , 2017 , 16, 322-323	3.1	
13	New developments in the management of hepatitis C virus infection: focus on boceprevir. <i>Biologics: Targets and Therapy</i> , 2012 , 6, 249-56	4.4	
12	Treatment of hepatitis C in the post-transplant setting. <i>Digestive and Liver Disease Supplements</i> , 2011 , 5, 26-29		
11	Reply:. <i>Hepatology</i> , 2009 , 49, 2126-2126	11.2	
10	Management of Hepatitis C in Patients with End-stage Renal Disease. <i>Current Hepatitis Reports</i> , 2010 , 9, 38-46		
9	Recurrence of hepatitis C after liver transplantation. <i>Transplantation Proceedings</i> , 2005 , 37, 3311-2	1.1	
8	Emerging Management of Hepatitis C in Transplant 2020 , 1-20		
7	HCV Recurrence: Predictors and Outcomes After Liver Transplantation 2016 , 35-54		
6	The AuthorsRRReply: Tacrolimus Trough Concentrations After Liver Transplantation: Back to the Future. <i>Transplantation</i> , 2020 , 104, e115-e116	1.8	

- 5 Emerging Management of Hepatitis C in Transplant **2021**, 951-969
- 4 Cardiovascular risk and liver transplantation in HIV patients. Are HIV infected liver transplant recipients at higher risk?. *Journal of Liver Transplantation*, **2021**, 1, 100005
- 3 Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Eradication. *Transplantation*, **2018**, 102, S3 1.8
- 2 High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. *Annals of Hepatology*, **2015**, 14, 477-86 3.1
- 1 Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir/Sofosbuvir Plus Ribavirin Pretransplant. *Annals of Hepatology*, **2017**, 16, 322-323 3.1